A succession of new vaccination approvals created by Novavax

Biotech company Novavax Inc. (NVAX) has recently received several approvals for its COVID-19 vaccine. By the beginning of a new wave of coronavirus, the developer will have the opportunity to sell the vaccine in several markets to patients aged 12 and older. Reports of new approvals supported Novavax quotes, which have increased by almost 10% over the past month. At the auction on July 29, NVAX stock was worth $56.41. Recall that Novavax received permission from the US Food and Drug Administration (FDA) two weeks ago to use the Nuvaxovid coronavirus vaccine in emergencies. 

The company later announced its two-dose vaccine by the Advisory Committee of the U.S. Centers for Disease Control and Prevention for adult patients aged 18 and older. Novavax has also received expanded approval in international markets. The Ministry of Health, Labor and Welfare of Japan (MHLW) has authorized the use of the Nuvaxovid vaccine for children aged 12 to 17 years. 

In April, the Novavax COVID-19 vaccine in this country was for adults 18 years and older. The example of Japanese regulators followed by the Australian Therapeutic Goods Agency (TGA), which also allowed the vaccination of Nuvaxovid to children aged 12 to 17 years. Novavax reported that its COVID-19 vaccine showed 90% efficacy in phase III trials. To date, the use of Nuvaxovid for adults is allowed in 40 countries. Novavax is awaiting FDA approval for its booster dose of the vaccine in the coming months.